IP 501
Latest Information Update: 19 Sep 2003
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Developer Department of Veterans Affairs; Indevus Pharmaceuticals; National Institutes of Health (USA); Nonindustrial source
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver disorders
Most Recent Events
- 17 May 2003 Discontinued - Phase-III for Liver disorders in Canada (PO)
- 17 May 2003 Discontinued - Phase-III for Liver disorders in Europe (PO)
- 17 May 2003 Discontinued - Phase-III for Liver disorders in Japan (PO)